Clinical Evidence and Pharmacologic Profiles of New and Emerging Therapies for gMG and CIDP
hosted byProjects In Knowledge Inc. (PIK)Clinical Evidence and Pharmacologic Profiles of New and Emerging Therapies for gMG and CIDP is organized by Projects In Knowledge Inc. (PIK).
Release Date: Jun 12, 2023
Termination Date: Jun 11, 2024
Activity Goal:
The goal is to provide clinicians with a resource to help them understand the key principles of rare neuromuscular diseases to improve and optimize patient outcomes.
Learning Objective(s):
• Identify the unmet needs in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) and the limitations associated with conventional and existing treatments.
• Evaluate the potential treatment targets and benefits of new and emerging medications for the management of gMG.
• Analyze the potential treatment targets and benefits of new and emerging medications for the management of CIDP.
Additional details will be posted as soon as information is available.
